Myriad Genetics (MYGN) Gross Profit (2009 - 2026)

Myriad Genetics has disclosed Gross Profit across 18 years of filings, most recently posting $137.6 million for Q1 2026.

• In Q1 2026, Gross Profit rose 2.53% year-over-year to $137.6 million; the TTM figure through Mar 2026 stood at $580.0 million (changed 0.34% YoY), while the FY2025 annual figure was $576.6 million, down 1.5% from the prior year.
• Gross Profit retreated to $137.6 million in Q1 2026, from $146.8 million in the prior quarter.
• Over the last five years, Gross Profit for MYGN reached as high as $151.8 million in Q2 2025 and fell as low as $59.1 million in Q4 2022.
• The 5-year median for Gross Profit is $134.3 million (2023), against an average of $128.0 million.
• Annual changes were most pronounced in 2022 — Gross Profit slumped 79.54% — and 2024, when it soared 84.02%.
• A 5-year view of Gross Profit shows it stood at $59.1 million in 2022, then soared by 38.75% to $82.0 million in 2023, then surged by 84.02% to $150.9 million in 2024, then decreased by 2.72% to $146.8 million in 2025, then fell by 6.27% to $137.6 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $137.6 million, $146.8 million, and $143.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.